Chief Executive Officer, NGM Biopharmaceuticals
Dr. David J. Woodhouse brings to Surrozen’s board more than 18 years of experience throughout the biopharmaceutical industry, as a scientist and with expertise in strategy, finance, and capital development for growing biotechnology companies. He currently serves as the Chief Executive Officer and a director at NGM Biopharmaceuticals. He previously served as NGM’s Chief Financial Officer for over three years. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.